法律意见书 北京市中伦律师事务所 关于华润双鹤药业股份有限公司 2025 年第二次临时股东会的 法律意见书 致：华润双鹤药业股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司 股东会规则》（以下简称"《股东会规则》"）、《律师事务所从事证券法律业 务管理办法》等法律、法规和规范性文件以及《华润双鹤药业股份有限公司章程》 （以下简称"《公司章程》"）的规定，北京市中伦律师事务所（以下简称"本 所"）作为华润双鹤药业股份有限公司（以下简称"公司"）的常年法律顾问， 指派律师出席公司 2025 年第二次临时股东会（以下简称"本次股东会"），并 依法出具本法律意见书。 本法律意见书仅就本次股东会的召集和召开程序是否符合法律、行政法规 及《公司章程》的规定，以及出席本次股东会人员的资格、召集人资格、会议表 决程序及表决结果是否合法有效发表意见，而不对本次股东会所审议的议案内 容以及该等议案所表述的相关事实或数据的真实性、准确性或合法性发表意 见。本次股东会通过网络投票系统进行投票的股东资格由网络投票系统提供机 构验证其身份。 为出具本法律意见书，本所律师列席了本次股东会，并根据有关法律、法 ...

2025 年第二次临时股东会 2025 年 9 月 9 日 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025-080 一、会议召开和出席情况 华润双鹤药业股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 本次会议是否有否决议案：无 (一) 股东会召开的时间：2025 年 9 月 9 日 (二) 股东会召开的地点：北京市朝阳区锐创国际中心 A 座 9 层 会议室 (三) 出席会议的普通股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 467 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数(股) | 637,745,280 | | 3、出席会议的股东所持有表决权股份数占公司有 | 61.3950 | | 表决权股份总数的比例(%) | | (四) 表决方式是否符合《公司法》及公司《章程》的规定，股东 会主持情况等。 1、会议采取现场及网络方式投票表决，表决程序符合《公司法》 和公司《章程》的规定。 2、 ...

Group 1 - The company announced the resignation of Vice President Liu Ziqin due to work arrangement reasons, effective immediately upon submission to the board [1] - Liu Ziqin has completed the necessary handover procedures, and her departure will not affect the company's normal operations and management [1] - The board expressed gratitude for Liu Ziqin's contributions during her tenure as Vice President [2]

（文章来源：证券日报） 证券日报网讯 9月5日晚间，华润双鹤发布公告称，公司董事会近日收到公司副总裁刘子钦女士提交的 书面辞职报告，其因工作安排原因，申请辞去副总裁职务，辞职申请自送达董事会之日起生效。 ...

Group 1 - The company Huaren Shuanghe (SH 600062) announced the resignation of its vice president Liu Ziqin due to work arrangement reasons, effective immediately upon submission to the board [1] - For the first half of 2025, Huaren Shuanghe's revenue composition is as follows: non-infusion products account for 75.13%, infusion products account for 25.98%, and inter-segment eliminations account for -1.11% [1] - As of the report date, Huaren Shuanghe has a market capitalization of 20.1 billion yuan [1] Group 2 - The article discusses the challenges faced by Haidilao, noting that its sub-brands have a survival rate of less than 50% [1]

刘子钦女士不存在应当履行而未履行的承诺事项，已按照相关规定 做好交接工作，其离任不会影响公司的正常运作及经营管理。 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 华润双鹤药业股份有限公司(以下简称"公司")董事会近日收到公 司副总裁刘子钦女士提交的书面辞职报告，其因工作安排原因，申请 辞去副总裁职务，辞职申请自送达董事会之日起生效。 一、提前离任的基本情况 | 姓名 | 离任 | 离任时间 | | 原定任期 | | 离任原因 | 是否继续在上 市公司及其控 | 是否存在未 履行完毕的 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 职务 | | | 到期日 | | | | | | | | | | | | | 股子公司任职 | 公开承诺 | | 刘子钦 | 副总裁 | 2025 | 年 | 2027 7 | 年 | 工作安排 | 否 | 否 | | | | 9 月 5 日 | | 月 10 | 日 | | | | 公司董事会对刘子钦女士担任副总裁职务 ...

Core Viewpoint - The company announced the resignation of its Vice President Liu Ziqin due to work arrangement reasons, effective immediately upon delivery of the resignation letter to the board [1] Group 1 - The resignation was formally communicated to the board on September 5 [1] - Liu Ziqin's resignation is attributed to personal work arrangements [1]

Core Viewpoint - The company is focusing on clinical needs and steadily expanding its research pipeline in key areas such as oncology, antiviral treatments, and ophthalmology, with a commitment to enhancing innovation in drug development [1] Group 1: Drug Development Progress - The company has 15 projects progressing steadily in its innovation pipeline [1] - The modified new drug Panxin®-Mercaptopurine Tablets (Ⅱ) has been approved for production, filling a gap in precision treatment for childhood leukemia in China, achieving a balance between safety and efficacy [1] - The first-class anti-tumor drug DC50292A has received clinical approval from both the National Medical Products Administration and the FDA [1] - The first-class anti-tumor new drug DC05F01 is continuing to enroll participants for its Phase II clinical trial [1] - The 1.1 class biological drug J002 for treating dry eye syndrome has obtained clinical implied approval [1] Group 2: Future Directions - The company plans to accelerate its layout in major diseases, small molecule innovative drugs, and small nucleic acid drugs [1] - There is a continuous emphasis on strengthening independent innovation and cutting-edge technology reserves [1] - The company aims to comprehensively speed up its research and development transformation process [1]

Market Performance - The Artemisinin concept index rose by 0.17%, ranking third among concept sectors, with three stocks increasing in value, including Baihua Medicine which hit the daily limit, and Fosun Pharma and China Resources Sanjiu which rose by 0.39% and 0.05% respectively [1] - The top gainers in the Artemisinin sector were Baihua Medicine, Fosun Pharma, and China Resources Sanjiu, while the biggest losers included Delong Huineng, New Harmony, and Zhejiang Medicine, which fell by 3.33%, 1.18%, and 1.17% respectively [1] Capital Flow - The Artemisinin concept sector experienced a net outflow of 58 million yuan in main capital, with Baihua Medicine receiving the highest net inflow of 109 million yuan, followed by China Resources Sanjiu and Zhejiang Medicine with net inflows of 14.16 million yuan and 5.79 million yuan respectively [2] - The net inflow ratios for Baihua Medicine, China Resources Sanjiu, and Zhejiang Medicine were 29.47%, 5.98%, and 2.65% respectively, indicating strong interest in these stocks [3] Stock Performance Details - Baihua Medicine had a daily increase of 10.03% with a turnover rate of 9.48% and a main capital flow of 108.91 million yuan, leading the sector [3] - Other notable stocks included China Resources Sanjiu with a slight increase of 0.05% and a turnover rate of 1.18%, and Zhejiang Medicine which decreased by 1.17% with a turnover rate of 1.48% [3][4]

Core Viewpoint - Recently, China Resources Double Crane announced that its subsidiary, Zhejiang Xinsai Pharmaceutical Co., Ltd., received a GMP compliance inspection notice for the active pharmaceutical ingredients of Fenofibrate and Azilsartan from the Zhejiang Provincial Drug Administration [2] Group 1 - The company has received regulatory approval for two key pharmaceutical products [2] - The approval is significant for the company's production capabilities and market positioning in the pharmaceutical industry [2] - This development may enhance the company's competitive edge in the active pharmaceutical ingredient market [2]